# AstraZeneca: Phase 3 study completed, 130 enrolled (Eosinophilic Asthma)

**Score:** 75/100

| Field | Value |
|---|---|
| Sponsor | AstraZeneca |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment |
| NCT ID | NCT06750289 |
| Phase | Phase 3 |
| Status | completed |
| Conditions | Eosinophilic Asthma |
| Intervention types | combination product |
| Target enrollment | 130 |
| Site countries | United States, Bulgaria, Canada, China, France, Germany, Hong Kong, Ireland, Italy, Norway, Spain, Switzerland |
| Posted | 2024-12-27 |
| Planned start | 2025-03-28 |
| Event | Completed |
| Event date | 2026-09-21 |
| Last update posted | 2026-10-16 |

## Why this score
- Industry sponsor (buys outsourced services).
- Completed: closeout, analysis and the next study ahead.
- Phase 3: multi-site, larger budget.
- 130 participants planned.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT06750289). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.